z-logo
open-access-imgOpen Access
Production and Roles of Glial Tissue Inhibitor of Metalloproteinases-1 in Human Immunodeficiency Virus-1-Associated Dementia Neuroinflammation: A Review
Author(s) -
C. Chao,
Anuja Ghorpade
Publication year - 2009
Publication title -
american journal of infectious diseases
Language(s) - English
Resource type - Journals
eISSN - 1558-6340
pISSN - 1553-6203
DOI - 10.3844/ajidsp.2009.307.313
Subject(s) - neuroinflammation , dementia , matrix metalloproteinase , human immunodeficiency virus (hiv) , medicine , microglia , neuroscience , immunology , inflammation , biology , pathology , disease
Problem statement: Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and its cognate targets, the Matrix Metalloproteinases (MMPs), were differentially expressed in human brain samples with or without HIV-1 infection or HIV-1 Encephalitis (HIVE). Approach: A through literature review demonstrated that cell culture models of Central Nervous System (CNS) cell types had been used to illustrate the intricate temporal patterns of TIMP-1/MMP expression, regulated by a variety of inflammatory cytokines. Results: As MMPs and TIMP-1 can significantly altered the extracellular environment and cell signaling, the differential regulation of TIMP-1/MMP expression in neuroinflammation can impact neuronal function and survival in disease conditions. TIMP-1 pro-survival effects had been demonstrated in a variety of cell types including CNS neurons, protecting cells from a wide range of stress and insults. TIMP-1, also known to interact with non-MMP targets, altered cell behavior. In this review, we discussed the possibility that the upregulation of TIMP-1 by glia in acute neuroinflammation may be a neuroprotective response. Conclusion: It will be important to delineate the effects of TIMP-1 on neurons and identify receptors and downstream signaling pathways, in order to evaluate TIMP-1 as a therapeutic strategy for neuroinflammatory and neurodegenerative diseases

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here